Evaluation of pain relief treatment and timelines inemergency care in six european countries and Australia

Abstract

Inadequate relief of pain is common in prehospital and hospital emergency department (ED) settings. We investigated pain treatments and timelines in patients receiving pre-hospital and hospital ED care to provide insight into potential approaches to reduce theburden of trauma-related pain. Patients and methods: In this observational, retrospective chart review, patients hadreceived emergency care for musculoskeletal trauma injuries and analgesic treatment formoderate-to-severe pain in Belgium, France, Germany, Italy, Spain or Sweden. As inhaledlow-dose methoxyflurane (LDM) is used extensively in Australia but was not widely availablein Europe at the time of this analysis, data from Australia were collated to provide insight into the potential utility of this analgesic in Europe. The primary endpoint was time toadministration of first pain relief treatment following arrival of paramedic/ED care. Results: Randomly selected physicians (n=189) collated data from 856 patients (Europe:n=585; Australia: n=271) via an online survey. Time to first pain relief treatment varied between countries and was significantly longer across Europe versus Australia (mean [SD]38.1 [34.7] vs 29.9 [35.5] mins; P=0.0017). Patients from Australia who received LDM experience a shorter mean (SD) time to first pain treatment following arrival of emergencycare versus patients who received other analgesics (propensity score matched [n=85] pergroup: 21.7 [24.2] vs 39.1 [43.0] mins; P=0.0013). Across all countries, mean (SD) time to first analgesic was shorter when treatment was administered by paramedics versus hospitalED staff (15.7 [14.7] vs 49.1 [38.4] mins). Conclusions: While there was a large variation in analgesia time lines across countries,mean times are shorter in Australia compared with Europe overall. In Australia, use of LDM was associated with a significantly shorter time from emergency assistance to first pain treatment compared with non-LDM treatments. Further studies are needed to investigate the utility of LDM in Europe.